// App-Quantinova.ai

: Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort

Researchers

Presenter

  • Sofia Chiatamone Ricci

Principal Investigators

  • Stefania Trasarti

  • Cristina Santoro

  • Massimo Breccia

  • Luisa Bizzoni

  • Ida Carmosino

  • Marco Mancini

  • Erminia Baldacci

  • Matteo Molica

  • Daniela De Benedittis

  • Giulia Ciotti

  • Elena Mariggi

  • Sara Mohamed

  • Maria Lucia De Luca

  • Giacinta Pistilli

  • Annalisa Mancuso

  • Chiara Lisi

  • Daniela Diverio

  • Marco Vignetti

  • Robin Fo

  • Roberto Latagliata

  • Antonietta Ferretti

Medical Centers

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Division of Cellular Biotechnologies and Hematology, University Sapienza,Roma,Italy

  • Division of Cellular Biotechnologies and Hematology, University Sapienza,Roma,Italy

  • Institute of Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University, Policlinico Umberto I, Rome, Rome, Italy

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Genetic Disorder

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Essential thrombocythemia

  • Intracerebral hemorrhage

  • Myeloid neoplasms

  • Venous thrombosis

Biomarkers

  • N-Acylethanolamine acid amidase

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A